Skip to main content
. Author manuscript; available in PMC: 2015 Jun 1.
Published in final edited form as: Cancer Chemother Pharmacol. 2014 Apr 12;73(6):1263–1271. doi: 10.1007/s00280-014-2463-3

Table 1.

Selective inhibition of the proteasome chymotrypsin-like and caspase-like activity by BU-32

Cell line Chymotrypsin-like Caspase-like Trypsin-like
IC50 (nM) IC50 (nM) IC50 (nM)
BU-32 Bortezomib BU-32 Bortezomib BU-32 Bortezomib
RPMI822G 4.2 ± 0.38 6.7 ± 0.48 13.5 ± 0.87 15.1 ± 0.92 >18 >18
MM1S 2.9 ± 0.18 4.5 ± 0.32 9.2 ± 0.32 12.1 ± 0.87 >18 >18
MM1R 7.5 ± 0.56 8.6 ± 0.19 9.0 ± 0.42 10.1 ± 0.67 >18 >18
U266 6.1 ± 0.42 8.4 ± 0.12 13.4 ± 0.56 18.0 ± 0.78 >18 >18